In summary, these data suggest one of neuroprotective effects of GLP-1R agonists is inhibiting neuronal apoptosis
JAMA Dermatology, 158 (3), 266
Unless legislative changes occur, Medicare patients paying out-of-pocket will face high costs, though some price-cap frameworks could limit specific Medicare copays to approximately $50 to $245 per month
doi: 10.1080/13543784.2024.2377319 23
Clinical Impact of ITCA 650, a novel drug-device GLP-1 receptor agonist, in uncontrolled type 2 diabetes and very high baseline HbA1c: The FREEDOM-1 HBL (high baseline) study
This is significant because MASLD/MASH affects an estimated 30% of the global population, and we currently have very limited pharmacological options